Recent studies into retatrutide peptide demonstrate promising outlook for addressing weight and type 2 diabetes. The compound, a dual agonist of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, looks to provide enhanced body mass and blood sugar control in contrast to existing medications. Additional research efforts are ne